Related Experiment Videos

Hodgkin's disease. Treatment of the young child

S S Donaldson1, M P Link

  • 1Department of Radiation Oncology, Stanford University Medical Center, California.

Insights

Younger patients diagnosed with Hodgkin's disease have better cure rates and survival outcomes. Treatment aims to maximize quality of life and minimize complications for children, focusing on specialized care.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Research

Background:

  • Age is a critical prognostic factor in Hodgkin's disease.
  • Younger patients generally experience better outcomes compared to adults.
  • Histologic and stage variations exist across different age groups.

Purpose of the Study:

  • To analyze the impact of age on Hodgkin's disease prognosis and survival.
  • To evaluate treatment strategies and outcomes in pediatric Hodgkin's disease.
  • To highlight the unique challenges and considerations in managing pediatric Hodgkin's disease.

Main Methods:

  • Retrospective analysis of patient data based on age at diagnosis.
  • Comparison of relapse-free survival and overall survival rates across age cohorts.
  • Review of treatment protocols, including low-dose radiation and chemotherapy, for younger children.

Main Results:

  • Patients diagnosed at younger ages (<10 and 11-16 years) showed significantly higher relapse-free survival (80% and 74%) and 26-year survival (74%) compared to adults (64% and 37%).
  • These age-related differences persisted across different disease stages.
  • Survival rates of 85% or greater are achievable in younger children with appropriate treatment, such as low-dose radiation and multiagent chemotherapy.

Conclusions:

  • Age at diagnosis is a significant determinant of cure rate and survival in Hodgkin's disease.
  • Pediatric Hodgkin's disease requires tailored treatment approaches to maximize cure rates while minimizing long-term sequelae like skeletal abnormalities and sterility.
  • Management in specialized regional centers is crucial for optimizing outcomes and quality of life in children with Hodgkin's disease.

Related Concept Videos